Let’s
Find a
Better Way
Thank you for joining the STRIVE Study to help detect cancer early
Your continued participation in study follow-up will help us to develop this blood test.
The STRIVE Study enrolled women undergoing screening mammography at Cleveland Clinic, Henry Ford Health System, Mayo Clinic, Sarah Cannon, Scottsdale Medical Imaging (SMIL), and Sutter Health. The success of the STRIVE Study depends on our ability to follow participants for cancer events over time. This follow-up is critical to the development of a blood test for the early detection of cancer. The STRIVE Study team will be reaching out to participants occasionally to collect study follow-up information. Additionally, study researchers will also be actively monitoring electronic health records for up to 5 years from the time of enrollment to capture clinical outcome data, including cancer diagnoses. To learn more about study follow-up, use the appropriate link below.
Your contribution to STRIVE is helping the development of a blood test for early cancer detection
The earlier that cancer can be found, the better the chance of survival. The STRIVE Study will test a new technology being developed to detect small pieces of genomic material in the blood arising from cancers. To understand if this test can detect cancer early, the STRIVE Study enrolled women at the time of their screening mammogram and will actively monitor their electronic health records for five years to capture clinical outcome data, including cancer diagnoses.
